What is the highest dose of Mounjaro?

15 mg subcutaneous once weekly is the maximum adult dose. The pediatric ceiling for ages 10 and older is 10 mg per week.

How often do you inject Mounjaro?

Once per week, any day, any time of day, with or without meals. Pick a consistent weekly day.

How often should you increase your Mounjaro dose?

Not more than once every four weeks. The 4-week interval is the FDA-label minimum and the protocol used in every SURPASS and SURMOUNT trial to manage GI side effects.

When should you increase your Mounjaro dose?

When you have completed at least 4 weeks at the current dose, are tolerating it without severe side effects, and your A1C is still above target or your weight loss has plateaued before reaching your goal.

What is the best time of day to take Mounjaro?

Any time. The FDA label specifies once weekly with no time-of-day requirement. Pick whatever fits your schedule and stick with it.

What if I missed a Mounjaro dose?

If within 4 days of the scheduled day, take it as soon as you remember and resume the weekly schedule. If more than 4 days late, skip it and take the next dose on the regular day. Never double up.

How long should you hold Mounjaro before surgery?

Confirm with your surgical and anesthesia team. The common pattern is at least 1 week off before elective procedures requiring general anesthesia, because tirzepatide slows gastric emptying and raises aspiration risk during sedation.

Can you stay on 2.5 mg of Mounjaro long term?

For type 2 diabetes, no. The FDA label states 2.5 mg is for initiation only and not intended for glycemic control. After 4 weeks, the dose moves to 5 mg or higher.

Do you have to get to 15 mg of Mounjaro?

No. In SURPASS-2, 82% of patients on 5 mg and 86% on 10 mg reached A1C below 7%. Most patients reach their target before the maximum dose and stay at 5 mg or 10 mg long term.

Mounjaro Dosage Chart

Summary: Mounjaro titrates from 2.5 mg to a 15 mg ceiling in 2.5 mg steps every four weeks, and most type 2 diabetes patients land at 5 mg or 10 mg once A1C reaches target rather than climbing to the top.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The Mounjaro titration is six rungs of a ladder: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, all injected subcutaneously once weekly, with four weeks at each rung before the next step ^[1]. The 2.5 mg dose is the on-ramp and is not intended for glycemic control. Most type 2 diabetes patients in the SURPASS trials reached their A1C target at 5 mg or 10 mg and stopped climbing ^[2]. The 15 mg dose is the ceiling, not the goal.

The chart below is the FDA label schedule, with the maintenance-dose distribution from SURPASS, the rules for missed and late doses, and the math for converting brand doses to compounded vial volumes.

The standard Mounjaro titration chart

Week	Dose	Volume per injection	Purpose
1 to 4	2.5 mg	0.5 mL	Initiation, not for glycemic control
5 to 8	5 mg	0.5 mL	First maintenance option
9 to 12	7.5 mg	0.5 mL	Step up if A1C still above target
13 to 16	10 mg	0.5 mL	Common long-term maintenance
17 to 20	12.5 mg	0.5 mL	Step up if needed
21 onward	15 mg	0.5 mL	Maximum adult dose

Three rules govern every step on this chart and the FDA label states them plainly ^[1]:

The starting dose is 2.5 mg once weekly for four weeks. Initiation only. Do not use it as a maintenance dose for blood sugar control.
After four weeks, step to 5 mg. If glycemic control is adequate at 5 mg, stay there.
If more control is needed, increase in 2.5 mg increments after at least four weeks at the current dose. The adult ceiling is 15 mg. The pediatric ceiling for ages 10 and older is 10 mg.

Each brand pen, regardless of strength, contains 0.5 mL of solution. The concentration is what changes between pens, not the volume. A 2.5 mg pen is 2.5 mg per 0.5 mL (5 mg/mL). A 15 mg pen is 15 mg per 0.5 mL (30 mg/mL). You press the button, the pen delivers 0.5 mL, and the strength is determined by which pen you picked up.

A1C-target-guided dosing: why most people stop before 15 mg

The titration chart goes to 15 mg, but the prescribing protocol does not require you to get there. The label specifies that increases past 5 mg happen "if additional glycemic control is needed" ^[1]. That is the key phrase. If your A1C drops to target at 5 mg, you stay at 5 mg. If it does not, you step to 7.5 mg. The chart is a path you walk only as far as you need to.

In SURPASS-2, the head-to-head trial against semaglutide 1 mg, 1879 adults with type 2 diabetes were randomized to tirzepatide 5 mg, 10 mg, or 15 mg ^[2]. The results at 40 weeks:

Mean A1C reduction was 2.01% at 5 mg, 2.24% at 10 mg, and 2.30% at 15 mg.
The proportion of patients reaching A1C below 7% was 82% at 5 mg, 86% at 10 mg, and 86% at 15 mg.
The proportion reaching A1C below 5.7% (non-diabetic range) was 27% at 5 mg, 40% at 10 mg, and 46% at 15 mg.

The gap between 5 mg and 10 mg is real. The gap between 10 mg and 15 mg is small for glycemic outcomes. That is why endocrinologists often park patients at 5 mg or 10 mg if A1C lands in range, and reserve 15 mg for cases where blood sugar remains above target or weight loss is a co-primary goal.

Maintenance-dose distribution in clinical practice mirrors the trial data. Healthline's dosing review and the Lilly prescribing protocol both flag 5 mg and 10 mg as the most common long-term doses for type 2 diabetes ^[3]^[4]. Patients on Mounjaro specifically for diabetes management often never see 12.5 or 15 mg. Patients prescribed it off-label for weight loss, or those whose A1C remains stubbornly above 7%, are more likely to climb the full ladder.

Can you stay on 2.5 mg of Mounjaro?

For diabetes treatment, no. The label is explicit that 2.5 mg is for initiation and is not intended for glycemic control ^[1]. After four weeks, you escalate to at least 5 mg.

Two clinical caveats exist. First, if a patient cannot tolerate 5 mg due to nausea, vomiting, or severe GI symptoms, the prescribing physician may keep them at 2.5 mg longer than four weeks while symptoms settle, or step back down to 2.5 mg temporarily. This is a tolerability adjustment, not a maintenance protocol. Second, off-label weight loss prescribing sometimes uses 2.5 mg longer in patients who are losing weight at that dose and who do not tolerate higher doses, though the FDA-approved Zepbound label follows the same titration logic.

The honest answer to "can I just stay at 2.5 mg forever" is that you probably will not get the A1C reduction or weight loss the drug is capable of, because the 2.5 mg dose was not powered for either outcome in clinical trials.

Why doses get increased

The Mounjaro escalation exists for one reason: dose-dependent efficacy. Higher tirzepatide doses produce larger A1C reductions, larger weight reductions, and stronger appetite suppression ^[2]. The escalation schedule is not a marketing pattern. It is the only way to get a patient from a tolerable starting dose to a clinically meaningful maintenance dose without the GI side effect curve spiking enough to make them quit.

Tirzepatide slows gastric emptying. The gut adapts to this gradually. Starting at 5 mg or higher floods naïve patients with too much dual GIP/GLP-1 receptor activation at once, and the nausea-vomiting rate climbs sharply. Four weeks at each rung gives the gut time to recalibrate before the next signal increase.

Dose-skip and step-back protocols

Sometimes the next rung does not work. The FDA label and standard endocrinology practice recognize this with two adjustments:

Stepping back. If you escalate to a new dose and the side effects are intolerable (severe nausea lasting more than a week, vomiting affecting hydration, persistent abdominal pain), step down to the prior tolerated dose. Stay there for an additional four weeks before attempting the next step again. Some patients ratchet up to 7.5 mg, fall back to 5 mg, try again two months later, and succeed the second time.

Staying at a sub-maximal maintenance dose. If your A1C reaches target at 5 mg or 10 mg, the label does not require you to climb further ^[1]. Many patients on Mounjaro for diabetes maintain at one of these doses indefinitely. The trial data above supports this approach.

Pausing for procedures. Tirzepatide delays gastric emptying. Anesthesia teams now routinely ask about GLP-1 medication use before procedures requiring sedation, because residual stomach contents raise aspiration risk. The American Society of Anesthesiologists has issued guidance suggesting consideration of holding GLP-1 receptor agonists before elective surgery, with timing decisions individualized by the surgical and anesthesia team. The practical pattern many clinicians follow is to hold the weekly tirzepatide dose for at least one week (sometimes longer) before elective procedures with general anesthesia, and to resume after recovery. Always confirm the specific hold time with the prescriber and the anesthesia team for your procedure.

Conversion: brand doses to compounded vial concentrations

If you are using compounded tirzepatide from a pharmacy that ships multi-dose vials, the math is the same FDA dose, drawn from a different concentration. Each brand pen holds 0.5 mL of solution. Multi-dose compounded vials commonly come at 5 mg/mL, 10 mg/mL, or 20 mg/mL.

Use this formula:

mL to draw = dose in mg / vial concentration in mg/mL
U-100 insulin syringe units = mL × 100

Brand dose	5 mg/mL vial	10 mg/mL vial	20 mg/mL vial
2.5 mg	0.5 mL (50 units)	0.25 mL (25 units)	0.125 mL (12 to 13 units)
5 mg	1.0 mL (100 units)	0.5 mL (50 units)	0.25 mL (25 units)
7.5 mg	1.5 mL (150 units)	0.75 mL (75 units)	0.375 mL (37 to 38 units)
10 mg	2.0 mL (200 units)	1.0 mL (100 units)	0.5 mL (50 units)
12.5 mg	2.5 mL (250 units)	1.25 mL (125 units)	0.625 mL (62 to 63 units)
15 mg	3.0 mL (300 units)	1.5 mL (150 units)	0.75 mL (75 units)

A standard 1 mL U-100 insulin syringe maxes out at 100 units (1.0 mL). Doses above that volume require two injections or a larger syringe. Most patients on 5 mg/mL compounded vials switch to a more concentrated formulation (10 or 20 mg/mL) once they reach 7.5 mg or higher, specifically to keep each weekly dose to a single insulin syringe draw.

What to do if you miss or take a late dose

The FDA label rule is straightforward ^[1]:

Missed dose, within 4 days (96 hours) of the scheduled day: Inject the missed dose as soon as you remember, then resume the regular weekly schedule.
Missed dose, more than 4 days late: Skip it. Inject the next dose on the regularly scheduled day. Do not double up.
Changing your weekly injection day: This is allowed, as long as the gap between the two consecutive doses is at least 3 days (72 hours).

The 72-hour minimum gap is the floor. Closer than that and the tirzepatide from two doses stacks in plasma, which raises side effect risk without a meaningful efficacy gain. Tirzepatide has a five-day half-life, so steady-state pharmacokinetics tolerate a shift of a few days in either direction comfortably.

Can you take Mounjaro a day or two early? Yes, as long as you maintain at least 72 hours from the previous dose. Taking it two days early on a single occasion (say, you injected on Sunday last week and want to switch to Friday this week) is permitted. Just keep the new day going forward. Repeatedly taking it 2 to 3 days early week after week is not the same thing, and is closer to a dose-frequency change than a one-time adjustment.

When to step back instead of forward

Three signals tell you to hold or step down rather than escalate:

A1C is at target. If A1C is below 7% (or your individualized target) and stable, the case for further escalation is weak. Side effects rise with dose; A1C benefit does not, once you are in range.
Severe GI symptoms persist past the first two weeks at a new dose. Mild nausea in week 1 to 2 is expected and usually fades. Vomiting that interferes with hydration, abdominal pain that is severe or persistent, or signs of pancreatitis (severe upper abdominal pain radiating to the back) are reasons to call the prescriber and consider a step back or pause.
You hit the goal for the off-label weight-loss use. If your weight has stabilized at a healthy level and appetite suppression is adequate, the lowest dose that maintains that result is the right dose. Many off-label users on Mounjaro find a maintenance plateau at 7.5 or 10 mg.

Frequently asked questions about Mounjaro dosing

What is the highest dose of Mounjaro?: 15 mg subcutaneous once weekly is the maximum adult dose. The pediatric ceiling for ages 10 and older is 10 mg per week.
How often do you inject Mounjaro?: Once per week, any day, any time of day, with or without meals. Pick a consistent weekly day.
How often should you increase your Mounjaro dose?: Not more than once every four weeks. The 4-week interval is the FDA-label minimum and the protocol used in every SURPASS and SURMOUNT trial to manage GI side effects.
When should you increase your Mounjaro dose?: When you have completed at least 4 weeks at the current dose, are tolerating it without severe side effects, and your A1C is still above target or your weight loss has plateaued before reaching your goal.
What is the best time of day to take Mounjaro?: Any time. The FDA label specifies once weekly with no time-of-day requirement. Pick whatever fits your schedule and stick with it.
Can you take Mounjaro a day or two early?: Yes, as long as the gap from the previous dose is at least 3 days (72 hours). Maintain the new day going forward.
What if I missed a Mounjaro dose?: If within 4 days of the scheduled day, take it as soon as you remember and resume the weekly schedule. If more than 4 days late, skip it and take the next dose on the regular day. Never double up.
How long should you hold Mounjaro before surgery?: Confirm with your surgical and anesthesia team. The common pattern is at least 1 week off before elective procedures requiring general anesthesia, because tirzepatide slows gastric emptying and raises aspiration risk during sedation.
Can you stay on 2.5 mg of Mounjaro long term?: For type 2 diabetes, no. The FDA label states 2.5 mg is for initiation only and not intended for glycemic control. After 4 weeks, the dose moves to 5 mg or higher.
Do you have to get to 15 mg of Mounjaro?: No. In SURPASS-2, 82% of patients on 5 mg and 86% on 10 mg reached A1C below 7%. Most patients reach their target before the maximum dose and stay at 5 mg or 10 mg long term.

What this chart does not replace

The Mounjaro titration chart is a framework, not an individual prescription. Your A1C, weight, side effect profile, kidney function, other medications (especially insulin and sulfonylureas), and treatment goals all shape where you land on the ladder and how long you stay there. The numbers above come from the FDA label and the registration trials. Your prescriber decides which rung is yours.